Answers are grounded in this paper and cite their sources.
Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control. (Funded by GlaxoSmithKline; MENSA ClinicalTrials.gov number, NCT01691521.).
No takes yet. Share an insight, caveat, or question.
Ortega et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: